Virus-like particles (VLPs) hold great promise for the development of effective and affordable vaccines. VLPs, indeed, are suitable for presentation and efficient delivery to antigen-presenting cells of linear as well as conformational antigens. This will ultimately result in a crosspresentation with both MHC class I and II molecules to prime CD4(+) T-helper and CD8(+) cytotoxic T cells. This review describes an update on the development and use of VLPs as vaccine approaches for HIV.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1586/erv.12.152 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!